Novavax Stock Performance
| NVAX Stock | USD 7.31 0.18 2.52% |
Novavax has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.2331, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novavax will likely underperform. Novavax right now secures a risk of 6.42%. Please verify Novavax jensen alpha and semi variance to decide if Novavax will be following its current price movements.
Novavax Performance
1 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Novavax are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Novavax may actually be approaching a critical reversion point that can send shares even higher in October 2023. ...more
Last Split Factor 1:20 | Dividend Date 2019-05-10 | Last Split Date 2019-05-10 |
1 | EPS Estimate | 06/30/2023 |
2 | Entry to Agreement | 07/07/2023 |
3 | Financial Statements | 07/11/2023 |
4 | 130 per shot COVID vaccines Manufacturers warned against pri... | 07/13/2023 |
5 | EPS Reported | 08/08/2023 |
6 | Unclassified Event | 08/18/2023 |
7 | Why Novavax Stock Is Trading Higher Today | 08/21/2023 |
8 | Major Covid Vaccine Stocks Rise as Sensitization Efforts Set... | 08/22/2023 |
9 | Are These 2 Companies Next for Short Squeezes | 08/25/2023 |
10 | COVID is evolving quickly in white-tailed deer, study finds | 08/28/2023 |
11 | Should You Buy Novavaxs Stock Before the FDA Approves Its Ne... | 08/31/2023 |
12 | Coronavirus Cases Are on the Rise Should You Buy Vaccine Sto... | 09/05/2023 |
13 | This Down-on-Its-Luck Biotech Could Surge 150, Wall Street S... | 09/06/2023 |
14 | Novavax Stock Drops 13 percent on Pending FDA Authorization ... | 09/11/2023 |
15 | Does This Message From Moderna Mean Bad News for Novavax - T... | 09/21/2023 |
| Begin Period Cash Flow | 1.5 B |
Novavax |
Novavax Relative Risk vs. Return Landscape
If you would invest 753.00 in Novavax on June 28, 2023 and sell it today you would lose (22.00) from holding Novavax or give up 2.92% of portfolio value over 90 days. Novavax is currently generating 0.1429% in daily expected returns and assumes 6.418% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Novavax, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novavax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novavax's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novavax, and traders can use it to determine the average amount a Novavax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0223
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | NVAX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.42 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Novavax is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novavax by adding it to a well-diversified portfolio.
Novavax Fundamentals Growth
Novavax Stock prices reflect investors' perceptions of the future prospects and financial health of Novavax, and Novavax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novavax Stock performance.
| Return On Equity | -8.98 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.38) % | |||
| Current Valuation | 374.31 M | |||
| Shares Outstanding | 100.9 M | |||
| Price to Earning | (1.36) X | |||
| Price to Book | 49.52 X | |||
| Price to Sales | 0.48 X | |||
| Revenue | 1.6 B | |||
| Gross Profit | (156.04 M) | |||
| EBITDA | (633.77 M) | |||
| Net Income | (657.94 M) | |||
| Cash and Equivalents | 1.28 B | |||
| Cash per Share | 16.31 X | |||
| Total Debt | 549.78 M | |||
| Debt to Equity | 8.24 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | (8.00) X | |||
| Cash Flow from Operations | (415.94 M) | |||
| Earnings Per Share | (6.90) X | |||
| Market Capitalization | 719.45 M | |||
| Total Asset | 2.26 B | |||
| Retained Earnings | (4.28 B) | |||
| Working Capital | (756.55 M) | |||
| Current Asset | 287.26 M | |||
| Current Liabilities | 76.49 M | |||
About Novavax Performance
To evaluate Novavax Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Novavax generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Novavax Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Novavax market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Novavax's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for 2023 | ||
| Effect of Exchange Rate Changes on Cash | 4.5 M | 4.9 M | |
| Return on Investment | -7.2 K | -7.3 K | |
| Return on Average Assets | (0.26) | (0.29) | |
| Return on Average Equity | 1.70 | 1.83 | |
| Return on Invested Capital | 0.90 | 0.98 | |
| Return on Sales | (0.32) | (0.35) |
Things to note about Novavax performance evaluation
Checking the ongoing alerts about Novavax for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novavax help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novavax had very high historical volatility over the last 90 days | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.6 B. Net Loss for the year was (657.94 M) with loss before overhead, payroll, taxes, and interest of (156.04 M). | |
| Novavax currently holds about 1.28 B in cash with (415.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 71.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Does This Message From Moderna Mean Bad News for Novavax - The Motley Fool |
- Analyzing Novavax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novavax's stock is overvalued or undervalued compared to its peers.
- Examining Novavax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novavax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novavax's management team can help you assess the company's leadership.
- Pay attention to analyst opinions and ratings of Novavax's stock. These opinions can provide insight into Novavax's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide. Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.90) | Revenue Per Share 19.149 | Quarterly Revenue Growth 1.283 | Return On Assets (0.18) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.